Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

UK NICE’s MedTech Scan Will Give NHS Early View Of Innovation

Executive Summary

The UK National Institute for Health and Care Excellence is working on a new database of pre-launch-phase medtech products. The aim is to give NHS providers enough time to plan for the uptake of innovative technologies and, generally, to improve the pathway between development and adoption, says NICE medtech programs director Mirella Marlow.

You may also be interested in...



UK Outlook 2018: All To Play For In Technology Adoption With AAR Set For Take Off

Navigating the UK medtech innovation landscape is a notoriously complicated exercise, so industry is hoping the recently released Accelerated Access Review will have positive outcomes as 2018 unfolds. Andrew Davies, market access director for the Association of British Healthcare Industries,  says a simplified system of market access for medtech would bring benefits across the board.

UK Medtech To Leverage Accelerated Access Opportunity, Regardless Of The 'B' Word

The UK devices and diagnostics industries were quick to react to the long-overdue government response to the fall 2016 Accelerated Access Review, a proposal to fast-track innovation into the NHS to the benefit of UK science, patients and the economy. Coinciding with Brexit, it is a fine-sounding plan, but will there be practical follow-through for medtech too?

UK IVD Industry Finds New Voice And Appetite For Challenges Ahead

The association of the IVD industry in the UK, BIVDA, is undergoing a rebrand and proactively positioning itself to reinforce the value proposition that diagnostics represent for stakeholders. A new whitepaper on the theme was one of the highlights of an upbeat 2017 annual general meeting, in which Brexit and the EU IVDR for once were not the "stars" of the show.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT121614

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel